DOI QR코드

DOI QR Code

Human Papillomavirus Genotypes among Females in Mexico: a Study from the Mexican Institute for Social Security

  • Salcedo, Mauricio (Unidad de Investigacion Medica en Enfermedades Oncologicas, Hospital de Oncologia, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (Mexican Institute for Social Security: IMSS)) ;
  • Pina-Sanchez, Patricia (Unidad de Investigacion Medica en Enfermedades Oncologicas, Hospital de Oncologia, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (Mexican Institute for Social Security: IMSS)) ;
  • Vallejo-Ruiz, Veronica (Centro de Investigacion Biomedica de Oriente IMSS) ;
  • Monroy-Garcia, Alberto (Unidad de Investigacion Medica en Enfermedades Oncologicas, Hospital de Oncologia, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (Mexican Institute for Social Security: IMSS)) ;
  • Aguilar-Lemarroy, Adriana (Centro de Investigacion Biomedica de Oriente IMSS) ;
  • Cortes-Gutierrez, Elva I. (Centro de Investigacion Biomedica del Noreste IMSS) ;
  • Santos-Lopez, Gerardo (Centro de Investigacion Biomedica de Oriente IMSS) ;
  • Montoya-Fuentes, Hector (Centro de Investigacion Biomedica de Occidente IMSS) ;
  • Grijalva, Renan (Centro de Prevencion del Cancer en la Mujer Rigoberta Menchu Tum) ;
  • Madrid-Marina, Vicente (Centro de Investigacion sobre Enfermedades Infecciosas, Instituto Nacional de Salud Publica) ;
  • Apresa-Garcia, Teresa (Unidad de Investigacion Medica en Enfermedades Oncologicas, Hospital de Oncologia, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (Mexican Institute for Social Security: IMSS)) ;
  • Hernandez, Dulce M. (Division de Mejora a la Gestion de los Servicios de Salud IMSS) ;
  • Jave-Suarez, Luis F. (Centro de Investigacion Biomedica de Occidente IMSS) ;
  • Romero, Pablo (Unidad de Investigacion Medica en Enfermedades Oncologicas, Hospital de Oncologia, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (Mexican Institute for Social Security: IMSS)) ;
  • Poot, Albros (Unidad de Investigacion Medica en Enfermedades Oncologicas, Hospital de Oncologia, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (Mexican Institute for Social Security: IMSS)) ;
  • Salgado, Eduardo (Unidad de Investigacion Medica en Enfermedades Oncologicas, Hospital de Oncologia, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (Mexican Institute for Social Security: IMSS)) ;
  • Ramos-Gonzalez, Patricia (Centro de Investigacion Biomedica de Occidente IMSS) ;
  • Gonzalez-Hernandez, Rigoberto (Centro de Investigacion Biomedica de Occidente IMSS) ;
  • Canton, Juan C. (Departamento de Oncologia Ginecologica, UMAE Ginecologia del CMN de Occidente) ;
  • Jimenez-Aranda, Lucio (Centro de Investigacion Biomedica de Oriente IMSS) ;
  • Parra-Melquiadez, Miriam (Unidad de Investigacion Medica en Enfermedades Oncologicas, Hospital de Oncologia, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (Mexican Institute for Social Security: IMSS)) ;
  • Paniagua, Lucero (Unidad de Investigacion Medica en Enfermedades Oncologicas, Hospital de Oncologia, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (Mexican Institute for Social Security: IMSS)) ;
  • Mendoza, Monica (Unidad de Investigacion Medica en Enfermedades Oncologicas, Hospital de Oncologia, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (Mexican Institute for Social Security: IMSS)) ;
  • Arreola, Hugo (Unidad de Investigacion Medica en Enfermedades Oncologicas, Hospital de Oncologia, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (Mexican Institute for Social Security: IMSS)) ;
  • Villegas, Vanesa (Unidad de Investigacion Medica en Enfermedades Oncologicas, Hospital de Oncologia, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (Mexican Institute for Social Security: IMSS)) ;
  • Torres-Poveda, Kirvis (Centro de Investigacion sobre Enfermedades Infecciosas, Instituto Nacional de Salud Publica) ;
  • Bahena-Roman, Margarita (Centro de Investigacion sobre Enfermedades Infecciosas, Instituto Nacional de Salud Publica) ;
  • Gonzalez-Yebra, Beatriz (Hospital Regional de Alta Especialidad del Bajio, IMSS) ;
  • Taniguchi, Keiko (Unidad de Investigacion Medica en Enfermedades Oncologicas, Hospital de Oncologia, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (Mexican Institute for Social Security: IMSS)) ;
  • Rodea, Carlos (Departamento de Radioterapia, Hospital de Oncologia, CMN SXXI-IMSS) ;
  • Mantilla-Morales, Alejandra (Departamento de Patologia, Hospital de Oncologia, CMN SXXI-IMSS) ;
  • Mora-Garcia, Maria L. (Laboratorio Inmunobiologia-UMIEZ, FES-Zaragoza, UNAM) ;
  • Velazquez-Velazquez, Cindy K. (Unidad de Investigacion Medica en Enfermedades Oncologicas, Hospital de Oncologia, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (Mexican Institute for Social Security: IMSS)) ;
  • Cordova-Uscanga, Candelaria (Departamento de Patologia, Hospital de Oncologia, CMN SXXI-IMSS) ;
  • Peralta, Raul (Departamento de Matematicas, Facultad de Ciencias, UNAM) ;
  • Lopez-Romero, Ricardo (Unidad de Investigacion Medica en Enfermedades Oncologicas, Hospital de Oncologia, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (Mexican Institute for Social Security: IMSS)) ;
  • Marrero, Daniel (Unidad de Investigacion Medica en Enfermedades Oncologicas, Hospital de Oncologia, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (Mexican Institute for Social Security: IMSS)) ;
  • Bandala, Cindy (Unidad de Apoyo a la Investigacion, Instituto Nacional de Rehabilitacion) ;
  • Reyes-Leyva, Julio (Centro de Investigacion Biomedica de Oriente IMSS) ;
  • Furuya, Maria E. (Coordinacion de Investigacion en Salud, IMSS) ;
  • Almeida, Eduardo (Coordinacion de Investigacion en Salud, IMSS) ;
  • Galvan, Maria E. (Coordinacion de Investigacion en Salud, IMSS) ;
  • Grijalva, Israel (Coordinacion de Investigacion en Salud, IMSS)
  • Published : 2015.01.06

Abstract

Background: The aetiological relationship between human papillomavirus (HPV) infection and cervical cancer (CC) is widely accepted. Our goal was to determine the prevalence of HPV types in Mexican women attending at the Mexican Institute for Social Security from different areas of Mexico. Materials and Methods: DNAs from 2,956 cervical samples were subjected to HPV genotyping: 1,020 samples with normal cytology, 931 with low-grade squamous intraepithelial lesions (LGSIL), 481 with high grade HGSIL and 524 CC. Results: Overall HPV prevalence was 67.1%. A total of 40 HPV types were found; HPV16 was detected in 39.4% of the HPV-positive samples followed by HPV18 at 7.5%, HPV31 at 7.1%, HPV59 at 4.9%, and HPV58 at 3.2%. HPV16 presented the highest prevalence both in women with altered or normal cytology and HPV 18 presented a minor prevalence as reported worldwide. The prevalence ratio (PR) was calculated for the HPV types. The analysis of PR showed that HPV16 presents the highest association with CC, HPV 31, -33, -45, -52 and -58 also demonstrating a high association. Conclusions: The most prevalent HPV types in cervical cancer samples were -16, -18, -31, but it is important to note that we obtained a minor prevalence of HPV18 as reported worldwide, and that HPV58 and -52 also were genotypes with an important prevalence in CC samples. Determination of HPV genotypes is very important in order to evaluate the impact of vaccine introduction and future cervical cancer prevention strategies.

Keywords

Human papillomavirus;genotypes;cervical cancer;Mexico

References

  1. Bernard HU, Calleja-Macias IE, Terence Dunn S (2006). Genome variation of human papillomavirus types: Phylogenetic and medical implications. Int J Cancer, 118, 1071-6. https://doi.org/10.1002/ijc.21655
  2. Berumen J, Ordonez RM, Lazcano E, et al (2001). Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control study. J Natl Cancer Inst, 93, 1325-30. https://doi.org/10.1093/jnci/93.17.1325
  3. Bruni L, Diaz M, Castellsague X, et al (2010). Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis, 202, 1789-99. https://doi.org/10.1086/657321
  4. Chinchai T, Chansaeroj J, Swangvaree S, et al (2012). Prevalence of human papillomavirus genotypes in cervical cancer. Int J Gynecol Cancer, 22, 1063-8. https://doi.org/10.1097/IGC.0b013e318259d904
  5. Ciapponi A, Bardach A, Glujovsky D, et al (2011). Type-specific HPV prevalence in cervical cancer and high-grade lesions in Latin America and the Caribbean: systematic review and meta-analysis. PLoS one, 16, 25493.
  6. Clifford GM, Smith JS, Plummer M, et al (2003). Human papillomavirus types in invasive cervical cancer Worldwide: a meta-analysis. Br J Cancer, 88, 63-73. https://doi.org/10.1038/sj.bjc.6600688
  7. de Sanjose S, Quint WG, Alemany L, et al (2010) Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol, 11,1048-56. https://doi.org/10.1016/S1470-2045(10)70230-8
  8. Gonzalez-Losa MR, Rosado-Lopez I, Valdez-Gonzalez N, et al (2004). High prevalence of human papillomavirus type 58 in Mexican colposcopy patients. J Clin Virol, 29, 202-5.
  9. Guan P, Howell-Jones R, Li N, et al (2012). Human papillomavirus types in 115,789 HPV-positive women: A meta-analysis from cervical infection to cancer. Int J Cancer, 131, 2349-59. https://doi.org/10.1002/ijc.27485
  10. Illades-Aguiar B, Alarcon-Romero L del C, Antonio-Vejar V, et al (2010). Prevalence and distribution of human papillomavirus types in cervical cancer, squamous intraepithelial lesions, and with no intraepithelial lesions in women from Southern Mexico. Gynecol Oncol, 117, 291-6. https://doi.org/10.1016/j.ygyno.2010.01.036
  11. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  12. Li N, Franceschi S, Howell-Jones R, et al (2011). Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer, 128, 927-35. https://doi.org/10.1002/ijc.25396
  13. Lizano M, De la Cruz-Hernandez E, Carrillo-Garcia A, et al (2006) Distribution of HPV16 and 18 intratypic variants in normal cytology, intraepithelial lesions, and cervical cancer in a Mexican population. Gynecol Oncol, 102, 230-5. https://doi.org/10.1016/j.ygyno.2005.12.002
  14. Lizano M, Berumen J, Garcia-Carranca A (2009). HPV-related carcinogenesis: basic concepts, viral types and variants. Arch Med Res, 40, 428-34. https://doi.org/10.1016/j.arcmed.2009.06.001
  15. Lopez-Revilla R, Martinez-Contreras LA, Sanchez-Garza M, et al (2008). Prevalence of high-risk human papillomavirus types in Mexican women with cervical intraepithelial neoplasia and invasive carcinoma. Infect Agent Cancer, 3, 3. https://doi.org/10.1186/1750-9378-3-3
  16. Munoz N, Bosch FX, de Sanjose S, et al (2003). International Agency for Research on Cancer Multicenter Cervical Cancer Study Group: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med, 348, 518-27. https://doi.org/10.1056/NEJMoa021641
  17. Natphopsuk S, Settheethan-Ishida W, Pientong C, et al (2013). Human papillomavirus genotypes and cervical cancer in northeast Thaiand. Asian Pac J Cancer Prev, 14, 6961-4 https://doi.org/10.7314/APJCP.2013.14.11.6961
  18. Orozco-Colin A, Carrillo-Garcia A, Mendez-Tenorio A, et al (2010). Geographical variation in human papillomavirus prevalence in Mexican women with normal cytology. Int J Infec Dis, 14, 1082-7. https://doi.org/10.1016/j.ijid.2010.07.007
  19. Othman N, Othamn NH (2014). Detection of human papillomavirus DNA in routine cervical scrapping samples: use for a national cervical cancer scrrening program in a developing nation. Asian Pac J Cancer Prev, 15, 2245-9 https://doi.org/10.7314/APJCP.2014.15.5.2245
  20. Panigoro R, Susanto H, Novel SS, et al (2013). HPV genotyping linear assay test comparison in cervical cancer patients: implications for HPV prevalence and molecular epidemiology in a limited-resource area in Bandung, Indonesia. Asian Pac J Cancer Prev, 14, 5843-7 https://doi.org/10.7314/APJCP.2013.14.10.5843
  21. Peralta-Rodriguez R, Romero-Morelos P, Villegas-Ruiz V, et al (2012). Prevalence of human papillomavirus in the cervical epithelium of Mexican women: meta-analysis. Infect Agent Cancer, 7, 34. https://doi.org/10.1186/1750-9378-7-34
  22. Pina-Sanchez P, Hernandez-Hernandez DM, Lopez-Romero R, et al (2006). Human papillomavirus-specific viral types are common in Mexican women affected by cervical lesions. Int J Gynecol Cancer, 16, 1041-7. https://doi.org/10.1111/j.1525-1438.2006.00458.x
  23. Pina-Sanchez P, Hernandez-Hernandez DM, Taja-Chayeb L, et al (2011). Polymorphism in exon 4 of TP53 gene associated to HPV 16 and 18 in Mexican women with cervical cancer. Med Oncol, 28, 1507-13. https://doi.org/10.1007/s12032-010-9599-8
  24. Sanchez-Anguiano LF, Alvarado-Esquivel C, Reyes-Romero MA, Carrera-Rodriguez M (2006). Human papillomavirus infections in women seeking cervical Papanicolaou of Durango, Mexico: prevalence and genotypes. BMC Infect Dis, 6, 27. https://doi.org/10.1186/1471-2334-6-27
  25. Serrano B, Alemany L, Tous S, et al (2012). Potential impact of a nine-valent vaccine in human papilloma virus related cervical disease. Infect Agent Cancer, 7, 38. https://doi.org/10.1186/1750-9378-7-38
  26. Shi W, Liu J, Huang Y, Qiao L (2001). Papillomavirus pseudovirus: a novel vaccine to induce mucosal and systemic cytotoxic T-lymphocyte responses. J Virol, 75, 10139-48. https://doi.org/10.1128/JVI.75.21.10139-10148.2001
  27. Sui S, Jiao Z, Niyazi M, Sulaiya, et al (2013). Genotype distribution and behavioral risk factor analysis of human papillomavirus infection in Uyghur women. Asian Pac J Cancer Prev, 14, 5861-5 https://doi.org/10.7314/APJCP.2013.14.10.5861
  28. Torroella-Kouri M, Morsberger S, Carrillo A, et al (1998). HPV prevalence among Mexican women with neoplastic and normal cervices. Gynecol Oncol, 70, 115-20. https://doi.org/10.1006/gyno.1998.5055
  29. Tota JE, Chevarie-Davis M, Richardson LA, Devries M, Franco EL (2011). Epidemiology and burden of HPV infection and related diseases: implications for prevention strategies. Prev Med, 53, 12-21. https://doi.org/10.1016/j.ypmed.2011.08.017
  30. Velazquez-Marquez N, Paredes-Tello MA, Perez-Terron H, et al (2009). Prevalence of human papillomavirus genotypes in women from a rural region of Puebla, Mexico. Int J Infect Dis, 13, 650-5.
  31. Velazquez-Marquez N, Jimenez-Aranda LJ, Sanchez-Alonso P, et al (2010). Human Papillomavirus infection in women from Tlaxcala, Mexico. Brazil J Microbiol, 41, 749-56. https://doi.org/10.1590/S1517-83822010000300027
  32. Wang S, Wei H, Wang N, et al (2012). The prevalence and role of human papillomavirus genotypes in primary cervical screening in the northeast of China. BMC Cancer, 12, 160. https://doi.org/10.1186/1471-2407-12-160
  33. Wu EQ, Zhang GN, Yu XH, et al (2008). Evaluation of high-risk human papillomaviruses type distribution in cervical cancer in Sichuan province of China. BMC Cancer, 8, 202. https://doi.org/10.1186/1471-2407-8-202

Cited by

  1. Distribution of Carcinogenic Human Papillomavirus Genotypes and Association to Cervical Lesions among Women in Fez (Morocco) vol.11, pp.1, 2016, https://doi.org/10.1371/journal.pone.0146246
  2. Prevalence of human papillomavirus infection among women presenting for cervical cancer screening in Chile, 2014–2015 vol.205, pp.6, 2016, https://doi.org/10.1007/s00430-016-0473-y
  3. Prevalence of high-risk human papillomavirus infection among women in Shaanxi province of China: A hospital-based investigation vol.89, pp.7, 2016, https://doi.org/10.1002/jmv.24748
  4. Prevalence of High-Risk Genotypes of Human Papillomavirus: Women Diagnosed with Premalignant and Malignant Pap Smear Tests in Southern Ecuador vol.2017, pp.1098-0997, 2017, https://doi.org/10.1155/2017/8572065
  5. Prevalence of Human Papillomavirus infection among Chilean women from 2012 to 2016 vol.89, pp.9, 2017, https://doi.org/10.1002/jmv.24805
  6. Association between HPV infection and prostate cancer in a Mexican population pp.1415-4757, 2018, https://doi.org/10.1590/1678-4685-gmb-2017-0331